Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Porphyria Cutanea Tarda

Dermatologic

Porphyria Cutanea Tarda (PCT) Clinical Trials and Treatments

Also called PCT, hepatic porphyria, uroporphyrinogen decarboxylase deficiency

Porphyria cutanea tarda (PCT) is the most common porphyria, representing approximately 80% of all porphyria cases, characterized by deficiency of uroporphyrinogen decarboxylase (UROD), the fifth enzyme in the heme synthesis pathway. The UROD deficiency leads to accumulation of uroporphyrin and other highly carboxylated porphyrins in the liver, blood and skin, driving the characteristic photosensitive cutaneous manifestations.

In plain words, porphyria cutanea tarda is a condition where an enzyme in the liver does not work well enough. Substances called porphyrins then build up, making skin on sun-exposed areas fragile and prone to blisters.

Get an email when new Porphyria Cutanea Tarda trials open or the FDA decides. Get alerts

Porphyria Cutanea Tarda

Where treatments stand, from ClinicalTrials.gov and FDA labels

FDA review0

No decision pending. FDA calendar

FDA-approved medicines0

No medicine's current FDA label names Porphyria Cutanea Tarda yet.

Porphyria Cutanea Tarda has no FDA-approved medicines, 0 open or active clinical trials (0 recruiting), and no pending FDA decision.

Labels checked October 21, 2026.Download the data

Latest for Porphyria Cutanea Tarda

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Porphyria Cutanea Tarda

Type I PCT (80% of cases) is acquired without UROD gene mutations, usually triggered by hepatitis C infection, HIV infection, alcohol consumption, estrogen use, iron overload, or other factors that impair hepatic UROD enzyme activity. Types II and III have underlying UROD mutations with type II being familial (inherited heterozygously) and type III sporadic due to somatic mutations or hemizygous inheritance patterns.

Keep reading about Porphyria Cutanea Tarda

The condition presents with photosensitive blistering on dorsal hands, forearms, face, and other sun-exposed areas triggered by minimal sun exposure. Blisters develop readily and heal with scarring, milia formation, and atrophic changes. Hyperpigmentation occurs with associated hypertrichosis and scleroderma-like skin changes on dorsal hands. Photofluorescence of urine under Wood's lamp reveals elevated porphyrins characteristic of the disease.

Hepatic involvement ranges from mild transaminitis to cirrhosis. Malignancy risk, particularly hepatocellular carcinoma, is increased in patients with underlying hepatitis C or cirrhosis.

What are the symptoms of Porphyria Cutanea Tarda?

These are common symptoms of Porphyria Cutanea Tarda, and how strong they are varies from person to person.

  • Fragile skin with blistering on sun-exposed areas
  • Hyperpigmentation and hypopigmentation
  • Hypertrichosis
  • Photosensitivity
  • Scarring and milia on hands
  • Liver disease in some cases

Who gets Porphyria Cutanea Tarda?

Type 1 PCT manifests typically in middle age (40-60 years) though can occur from adolescence to elderly individuals. Males affected more frequently than females overall, though gender distribution varies by type and triggering factors.

Estrogen-related cases predominantly affect women receiving hormone replacement therapy or oral contraceptives. More common in individuals of European descent though reported across all populations. Strong geographic variation with higher prevalence in Mediterranean regions and parts of Eastern Europe.

Hepatitis C coinfection significantly increases prevalence in certain populations. Alcohol abuse and HIV infection increase susceptibility across all ethnic groups. Genetic factors in types II and III show autosomal dominant inheritance with reduced penetrance.

Next steps: find trials you might fitsee what is being testedget help payingget alerts

How to get help paying for Porphyria Cutanea Tarda treatment

Charity funds and drugmaker programs for Porphyria Cutanea Tarda, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Charity funds
Status as each foundation showed it on November 16, 2026.

Open the full patient assistance finder →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Porphyria Cutanea Tarda

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Porphyria Cutanea Tarda resources

Reputable organizations and medical references for learning more about Porphyria Cutanea Tarda, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Porphyria Cutanea Tarda

This Porphyria Cutanea Tarda clinical trial finder lists studies as they become available, with eligibility criteria in plain English. Every trial comes from ClinicalTrials.gov.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

No active clinical trials yet

Porphyria Cutanea Tarda is a classified rare disease, but clinical trial activity for it is limited. That's part of why we track it. When a trial opens, Trial Friend will have it.

Get an email the moment a Porphyria Cutanea Tarda trial is registered on ClinicalTrials.gov.

Porphyria Cutanea Tarda patient communities

Facebook groups, Reddit communities and YouTube channels where Porphyria Cutanea Tarda patients, caregivers and advocacy groups talk.

Questions people ask about Porphyria Cutanea Tarda